Patents Examined by Marcos L Sznaidman
  • Patent number: 11324740
    Abstract: A method is provided for using of type-2 dopaminergic receptor agonists, for example, cabergoline, in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor (VEGF), particularly in treatment or prevention of diseases of an eye retina resulting from an increase in permeability of blood vessels and their angiogenesis using cabergoline, a dopaminergic D2 receptor agonist.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: May 10, 2022
    Inventor: Maciej Oseka
  • Patent number: 11312695
    Abstract: Methods and compositions are provided for increasing muscle hypertrophy, e.g., through the administration of novel combinations of natural products that inhibit SIRT1.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: April 26, 2022
    Assignees: The Regents of the University of California, University of Birmingham
    Inventors: Keith Baar, Andrew Philp, Simon Schenk
  • Patent number: 11306067
    Abstract: Compounds or pharmaceutical acceptable salts thereof of Formula (I), in which RM have the meaning described herein and pharmaceutical compositions thereof useful as antimicrobial and/or adjuvant:
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: April 19, 2022
    Assignee: Denovamed Inc.
    Inventors: Fan Wu, Erhu Lu, Shengguo Sun, Christopher J. Barden
  • Patent number: 11304960
    Abstract: Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.
    Type: Grant
    Filed: January 8, 2009
    Date of Patent: April 19, 2022
    Inventors: Chandrashekar Giliyar, Nachiappan Chidambaram, Mahesh V. Patel, Srinivasan Venkateshwaran
  • Patent number: 11285165
    Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: March 29, 2022
    Assignees: Lawrence Livermore National Security, LLC, The Regents of the University of California
    Inventors: Sally J. DeNardo, Gerald L. DeNardo, Rodney L. Balhorn
  • Patent number: 11242333
    Abstract: The present invention provides compounds of formula (I), compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, R12, R13, A, L, B, n, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: February 8, 2022
    Assignee: Kalvista Pharmaceuticals Limited
    Inventors: Hannah Joy Edwards, David Michael Evans, Premji Meghani, Andrew Richard Novak
  • Patent number: 11234943
    Abstract: Micronized trans-resveratrol is provided in 50-200 mg unit dosage form for use as a single unit dose daily for administration to human patients the treatment or prevention of non-alcoholic fatty liver disease and/or for the treatment, prevention or reversal of non-alcoholic hepatic steatosis, e.g. for administration to patients exhibiting evidence of fatty liver on ultrasonography. A reported study shows the effects of resveratrol micronized formulation in reducing the liver fat, decreasing hepatic enzymes, serum glutamate pyruvic transaminase (SGPT) and gamma-glutamyl transpeptidase (g-GT) and decreasing insulin resistance. At the end of the study, statistical analysis showed a strongly statistically significant reduction in the liver fat, which in some patients continued for an extended period after treatment was discontinued.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: February 1, 2022
    Inventor: Marios Andreou Theodotou
  • Patent number: 11234956
    Abstract: The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: February 1, 2022
    Assignee: SciSparc Ltd.
    Inventors: Ascher Shmulewitz, Elran Haber, Ephraim Brener
  • Patent number: 11215617
    Abstract: The present invention provides new compositions and methods for treating prostate cancer, e.g., drug-resistant prostate cancer, such as anti-androgen drug (e.g., enzalutamide) resistant and/or castration resistant prostate cancer (CRPC). These new compositions include, but are not limited to, pharmaceutical compositions that include an AR-V7 inhibitor, such as niclosamide. Alternatively, these new compositions can include, but are not limited to, pharmaceutical compositions that include an AKR1C3 inhibitor, such as indomethacin. These new methods include, but are not limited to, methods of administering an AR-V7 inhibitor, such as niclosamide, and/or an AKR1C3 inhibitor, such as indomethacin, to treat patients having prostate cancer. The present invention also provides methods of inhibiting androgen receptor variant expression, e.g. AR-V7, and methods of killing cells expressing AR-V7.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: January 4, 2022
    Assignees: The Regents of the University of California, U.S. Government Represented by the Department of Veterans Affairs
    Inventors: Allen C. Gao, Chengfei Liu, Wei Lou, Chong-xian Pan
  • Patent number: 11207290
    Abstract: The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: December 28, 2021
    Assignee: SciSparc Ltd.
    Inventors: Ephraim Brener, Elran Haber, Ascher Shmulewitz
  • Patent number: 11207331
    Abstract: Neuro-enhancing agents, compositions and methods are disclosed herein. Preferred neuro-enhancing agents of the present invention include progesterone and metabolites of progesterone, such as 3?-hydroxy-5?-pregnan-20-one (THP). These agents yield neuro-enhancing effects on neural cells that include neural progenitor and/or stem cells, whereby the agents stimulate mitosis of neural progenitor cells, stimulate neurite growth and organization, protect against neural loss, or one or more of these neural processes. Thus, the neuro-enhancing agents, compositions and methods disclosed herein are useful to reverse or prevent neurological disease or defects associated with neural loss or degeneration, such as Alzheimer's disease, neurological injuries, including injuries resulting from radiation therapy, and age-related neurological decline, including impairments in memory and learning.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: December 28, 2021
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Roberta Diaz Brinton, Jun Ming Wang
  • Patent number: 11207310
    Abstract: This invention provides a method of maintaining functional capacity, improving functional capacity, or lessening the decline of functional capacity in a human patient comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine such that a dose of 90-225 mg of pridopidine is administered to the patient per day, so as to thereby maintain functional capacity, improve functional capacity, or lessen the decline of functional capacity in the human patient.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: December 28, 2021
    Assignee: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michael Hayden, Spyridon Papapetropoulos, Juha-Matti Savola, Eli Eyal, Beth Borowsky, Igor Grachev
  • Patent number: 11202795
    Abstract: This application relates to the field of neurodegenerative diseases, more particularly to the field of Parkinson's disease. In particular, the disclosure describes that inhibitors reducing FAS activity can be used for treatment of Parkinson's disease, in particular, the treatment of patients suffering from Parkinson's disease having loss of function mutations in PINK1 or PARKIN genes.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: December 21, 2021
    Assignees: VIB VZW, Katholieke Universiteit Leuven, KU Leuven R&E
    Inventors: Patrik Verstreken, Vanessa Morais Epifânio, Melissa Vos
  • Patent number: 11202773
    Abstract: Drugs have been designed and developed with a structural motif allowing local bioavailability in the target organ but that are not broadly distributed at a concentration sufficient to illicit toxic side effects in non-targeted organs. The structural motif subjects the compound to be rapidly metabolized by metabolic enzymes before reaching the non-targeted organs.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: December 21, 2021
    Assignee: University of Houston System
    Inventor: Ming Hu
  • Patent number: 11197865
    Abstract: This invention provides uses for promethazine in the preparation of products to treat liver cancer and/or colon cancer and/or lung cancer. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug promethazine, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that promethazine has a new use as an anti-liver cancer and/or colon cancer and/or lung cancer medication, thus achieving a new purpose for an old drug.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: December 14, 2021
    Assignee: SHANGHAI JIAO TONG UNIVERSITY
    Inventors: Yongyong Shi, Zhijian Song
  • Patent number: 11197845
    Abstract: The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: December 14, 2021
    Assignee: SciSparc Ltd.
    Inventors: Ephraim Brener, Elran Haber, Ascher Shmulewitz
  • Patent number: 11192852
    Abstract: Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: December 7, 2021
    Assignee: REATA PHARMACEUTICALS, INC.
    Inventors: Eric Anderson, Gary L. Bolton, Bradley Caprathe, Xin Jiang, Chitase Lee, William H. Roark, Melean Visnick
  • Patent number: 11180460
    Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: November 23, 2021
    Assignee: Novartis AG
    Inventors: Daniela Angst, Francois Gessier, Anna Vulpetti
  • Patent number: 11179316
    Abstract: The present invention relates to an essential oil of Satureja montana comprising more than 60% by weight of geraniol and more than 5% by weight of trans-?-caryophyllene, in particular of Satureja montana L. ssp. variegata. The present invention also relates to the cosmetic use of an essential oil of Satureja montana comprising more than 60% by weight of geraniol and more than 5% by weight of trans-?-caryophyllene, in particular of Satureja montana L. ssp. variegata, for treating greasy skin and/or preventing greasy or greasy-prone skin and/or the associated aesthetic skin defects. The invention also relates to a cosmetic composition comprising said oil, to a non-therapeutic cosmetic care and/or cleansing treatment process for greasy skin, and also to said essential oil as a dermatological agent.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: November 23, 2021
    Assignee: L'OREAL
    Inventors: GĂ©raldine Lerebour, Pierre Lartaud, Bertrand Lacroix
  • Patent number: 11154527
    Abstract: A composition and method for the prophylaxis and treatment of topical fungal infections is provided. Generally, the composition includes an HMG-CoA reductase inhibitor and a carrier. In some forms, the composition further includes an anti-fungal agent. The method generally includes the steps of applying the composition topically once or multiple times. The composition and method can be used in combination with another form of fungal treatment, such as oral medications.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: October 26, 2021
    Assignee: The Children's Mercy Hospital
    Inventors: Susan Abdel-Rahman, Barry L. Preuett, J. Steven Leeder